Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Who is this study for? Pediatric patients over age 6 and adults with attention deficit hyperactivity disorder
What treatments are being studied? Methylphenidate
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 17
Healthy Volunteers: f
View:
• \- Youth ages 6-17 years with ADHD as a primary diagnosis
Locations
United States
Florida
University of Florida
RECRUITING
Gainesville
New York
Icahn School of Medicine at Mount Sinai
RECRUITING
New York
Ohio
Cincinnati Children's Hospital Medical Center
COMPLETED
Cincinnati
Washington
Seattle Children's Hospital
TERMINATED
Seattle
Contact Information
Primary
Beth Krone, PhD
beth.krone@mssm.edu
212-241-8012
Backup
John Markowitz, PharmD
Time Frame
Start Date: 2018-03-04
Estimated Completion Date: 2025-08
Participants
Target number of participants: 500
Treatments
Experimental: Methylphenidate
Youth with ADHD
Authors
Mark Stein, Tanya Froehlich
Related Therapeutic Areas
Sponsors
Collaborators: University of Florida, Seattle Children's Hospital, Children's Hospital Medical Center, Cincinnati, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Leads: Icahn School of Medicine at Mount Sinai